GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tenax Therapeutics Inc (NAS:TENX) » Definitions » ROE %

Tenax Therapeutics (Tenax Therapeutics) ROE % : -133.13% (As of Dec. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Tenax Therapeutics ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Tenax Therapeutics's annualized net income for the quarter that ended in Dec. 2023 was $-12.90 Mil. Tenax Therapeutics's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $9.69 Mil. Therefore, Tenax Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 was -133.13%.

The historical rank and industry rank for Tenax Therapeutics's ROE % or its related term are showing as below:

TENX' s ROE % Range Over the Past 10 Years
Min: -732.14   Med: -104.16   Max: -18.37
Current: -79.7

During the past 13 years, Tenax Therapeutics's highest ROE % was -18.37%. The lowest was -732.14%. And the median was -104.16%.

TENX's ROE % is ranked worse than
68.53% of 1360 companies
in the Biotechnology industry
Industry Median: -44.015 vs TENX: -79.70

Tenax Therapeutics ROE % Historical Data

The historical data trend for Tenax Therapeutics's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tenax Therapeutics ROE % Chart

Tenax Therapeutics Annual Data
Trend Apr14 Apr15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -108.00 -234.60 -732.14 -385.08 -160.80

Tenax Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -374.37 -71.37 -32.17 -64.37 -133.13

Competitive Comparison of Tenax Therapeutics's ROE %

For the Biotechnology subindustry, Tenax Therapeutics's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tenax Therapeutics's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tenax Therapeutics's ROE % distribution charts can be found below:

* The bar in red indicates where Tenax Therapeutics's ROE % falls into.



Tenax Therapeutics ROE % Calculation

Tenax Therapeutics's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-7.711/( (1.493+8.098)/ 2 )
=-7.711/4.7955
=-160.80 %

Tenax Therapeutics's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-12.904/( (11.287+8.098)/ 2 )
=-12.904/9.6925
=-133.13 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Tenax Therapeutics  (NAS:TENX) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-12.904/9.6925
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-12.904 / 0)*(0 / 11.787)*(11.787 / 9.6925)
=Net Margin %*Asset Turnover*Equity Multiplier
=N/A %*0*1.2161
=ROA %*Equity Multiplier
=N/A %*1.2161
=-133.13 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-12.904/9.6925
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-12.904 / -12.904) * (-12.904 / -13.364) * (-13.364 / 0) * (0 / 11.787) * (11.787 / 9.6925)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 0.9656 * N/A % * 0 * 1.2161
=-133.13 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Tenax Therapeutics ROE % Related Terms

Thank you for viewing the detailed overview of Tenax Therapeutics's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Tenax Therapeutics (Tenax Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Glen Lennox Drive, Suite 300, Chapel Hill, NC, USA, 27517
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction.
Executives
Robyn Hunter director 95 SAWYER ROAD, SUITE 110, WALTHAM MA 02453
Eliot M Lurier officer: Interim CFO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Chrisopher Thomas Giordano director, officer: CEO C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Armistice Capital, Llc director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd. director C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd director 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
June Sherie Almenoff director C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019
Michael H. Davidson director OMTHERA PHARMACEUTICALS, INC., 707 STATE ROAD, PRINCETON NJ 08540
Declan Doogan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP, 234 CHURCH STREET, NEW HAVEN CT 06510
Stuart Rich officer: Chief Medical Officer C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Illya Keith Maher director C/O ARMISTICE CAPITAL, 510 MADISON AVE., 7TH FLOOR, NEW YORK NY 10022
Ronald R Blanck director 2001 WALNUT HILL LANE, IRVING TX 75038
Gerald T Proehl director
James P. Mitchum director C/O NEPHROGENEX, INC., 79 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
John P Kelley officer: Chief Executive Officer C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502